SEC Form 4 · accession 0001354488-15-001663

Acer Therapeutics Inc. · ACER

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 8, 2015

Accepted (ET)

Apr 9, 2015 · 5:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001069308

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 8, 2015	M	44,087	—	A	85,000	D
Common Stock^F1,F2	Apr 8, 2015	M	518,707	—	A	1,037,414	I	see footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Subscription Rights (Right to Buy)^F1	$0.55	Apr 8, 2015	M	44,087	D	Mar 13, 2015	Apr 8, 2015	see footnote	44,087	0	D
Warrants (Right to Buy)^F1,F3	—	Apr 8, 2015	M	44,087	A	Apr 8, 2015	Apr 8, 2018	Common Stock	44,087	44,087	D
Subscription Rights (Right to Buy)^F2,F1	$0.55	Apr 8, 2015	M	518,707	D	Mar 13, 2015	Apr 8, 2015	see footnote	518,707	0	I
Warrants (Right to Buy)^F1,F2,F3	—	Apr 8, 2015	M	518,707	A	Apr 8, 2015	Apr 8, 2018	Common Stock	518,707	518,707	I

F1The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Opexa Therapeutics, Inc. (the "Company") to all holders of the Company?s common stock and to holders of certain of the Company's outstanding warrants. The subscription rights entitled each recipient thereof to purchase units ("Units"), each Unit consisting of one share of the Company?s common stock and one warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $0.55.
F2Held by Alkek and Williams Ventures, Ltd. ("Ventures"). Chaswil, Ltd. ("Chaswil") is the investment manager of Ventures and holds voting power and investment power with respect to the Issuer securities held by Ventures. Mr. Seaman is a registered principal of Chaswil and has shared voting power and/or investment power with respect to the Issuer securities held by Ventures. Mr. Seaman disclaims beneficial ownership of the shares held by Ventures except to the extent of any pecuniary interest therein.
F3Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of (i) $0.50 per share from the date of issuance through June 30, 2016 and (ii) $1.50 per share from July 1, 2016 through the expiration date of the warrants.